

Rec'd

27 MAR 2002

10/019,816

816

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application : MICHAEL VALENTINE AGREZ, ET AL.  
Application No. : 10/019,816  
Filed : December 28, 2001  
For : A METHOD OF MODULATING INTEGRIN MEDIATED  
CELLULAR ACTIVITY AND AGENTS USEFUL FOR SAME  
Examiner :  
Attorney's Docket : SW-046XX

Group Art Unit:

\*\*\*\*\*  
I hereby certify that this correspondence is being deposited with the  
United States Postal Service as first class mail in an envelope  
addressed to: Commissioner for Patents, Washington, D.C. 20231 on  
\_\_\_\_\_.

By: \_\_\_\_\_  
Charles L. Gagnebin III  
Registration No. 25,467  
Attorney for Applicant(s)

\*\*\*\*\*

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Washington, D.C. 20231

Sir:

It is desired to cite for the record in this application the  
enclosed references listed on the attached copy of PTO Form #1449. The  
paragraph(s) marked below are applicable to this Information Disclosure  
Statement.

- [X] (1) Pursuant to 37 C.F.R. § 1.97(b)(1) and (2), the attached  
Information Disclosure Statement is being filed within three  
months of the filing date of the above identified national  
application or within three months of the date of entry of the  
national stage as set forth in 37 C.F.R. § 1.491 of the above  
identified application. Accordingly, applicant(s) believes that  
no fee or statement under 37 C.F.R. § 1.97(e) is required.

Express Mail Number

EV 009950073 US

- [ ] (2) Pursuant to 37 C.F.R. § 1.97(b)(3), applicant(s) believes the attached Information Disclosure Statement is being filed before the mailing date of a first Office action on the merits. Accordingly, applicant(s) believes that no fee or statement under 37 C.F.R. § 1.97(e) is required.
- [ ] (3) Pursuant to 37 C.F.R. § 1.97(b)(4), applicant(s) believes the attached Information Disclosure Statement is being filed before the mailing date of a first Office action after the filing of a request for continued examination under § 1.114. Accordingly, applicant(s) believes that no fee or statement under 37 C.F.R. § 1.97(e) is required.
- [ ] (4) Pursuant to 37 C.F.R. § 1.97(c), the attached Information Disclosure Statement is being filed before the mailing date of a final action or a notice of allowance and is accompanied by:
  - [ ] a statement under 37 CFR § 1.97(e); or
  - [ ] the fee set forth in § 1.17(p).

PETITION UNDER 37 CFR § 1.97(d)

- [ ] (5) Pursuant to 37 CFR § 1.97(d), applicant(s) hereby petitions the Commissioner to consider the attached Information Disclosure Statement which is being filed on or before payment of the issue fee. This petition is accompanied by a statement under 37 C.F.R. § 1.97(e) and the petition fee set forth in 37 C.F.R. § 1.17(p).

STATEMENT UNDER 37 C.F.R. § 1.97(e)(1)

- [ ] (6) The undersigned hereby states that each item of information contained in the attached Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

STATEMENT UNDER 37 C.F.R. § 1.97(e)(2)

- [ ] (7) The undersigned hereby states that no item of information contained in the attached Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the attached Information Disclosure

Application No.: 10/019,816  
Filed: December 28, 2001  
Group Art Unit:

Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

The filing of this Information Disclosure Statement is not a representation by the undersigned as to personal knowledge of the contents of every word or phrase of the material enclosed or that reliance on other suitably trained professionals has not been made.


If a search report of a searching agency is enclosed identifying the nature of the relevance of each document, such a designation is deemed to satisfy 37 C.F.R. § 1.98(a)(3) even if in a foreign language because the codes are the same in all languages. However, applicant(s) does not necessarily adopt the position reflected by that report.

These references were cited in an International Search Report (copy enclosed) which issued in International Application No. PCT/AU00/00729 filed June 28, 2000.

The Commissioner is hereby authorized to charge payment of any additional fees associated with this communication or credit any overpayment to Deposit Account No. 23-0804. Triplicate copies of this letter are enclosed.

Respectfully submitted,

MICHAEL VALENTINE AGREZ, ET AL.

By:   
Charles L. Gagnebin III  
Registration No. 25,467  
Attorney for Applicant(s)

WEINGARTEN, SCHURGIN,  
GAGNEBIN & LEOVICI LLP  
Ten Post Office Square  
Boston, Massachusetts 02109  
Telephone: (617) 542-2290  
Telecopier: (617) 451-0313

Date: 3-27-2

CLG:kmw/264536-1  
Enclosure

Date: March 27, 2002

Page 2 of 2

Form PTO-1449 (REV. 07/01)		<b>U.S. DEPARTMENT OF COMMERCE</b> <b>PATENT AND TRADEMARK OFFICE</b>  INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>			ATTY. DOCKET NO. SW-046XX		APPLICATION NO. 10/019,816	
					APPLICANT: Michael Valentine Agrez, et al.			
					FILING DATE December 28, 2001		GROUP	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE*

FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES      NO
		WO 92/12236	7/23/1992	PCT			X

OTHER DOCUMENTS <i>(including Author, Title, Date, Pertinent Pages, etc.)</i>	
	The Journal of Biological Chemistry, Vol. 265, No. 20, 1990, Sheppard, et al., "Complete Amino Acid Sequence of a Novel Integrin $\beta$ Subunit ( $\beta_6$ ) Identified in Epithelial Cells Using the Polymerase Chain Reaction", pp. 11502-11507
	Cell Growth and Differentiation, Vol. 8, 1997, Gotoh, et al., "Cross-Linking of Integrins Induces Tyrosine Phosphorylation of the Proto-Oncogene Product Vav and the Protein Tyrosine Kinase Syk in Human Factor-dependent Myeloid Cells", pp. 721-729
	The Journal of Cell Biology, Vol. 136, No. 6, 1997, Lin, et al., "Integrin-mediated Activation of MAP Kinase is Independent of FAK: Evidence for Dual Integrin Signaling Pathways in Fibroblasts", pp. 1385-1395
	The International Journal of Biochemistry & Cell Biology, Vol. 32, 2000, Coppolino and Dedhar, "Bi-directional signal transduction by integrin receptors", pp. 171-188

EXAMINER	DATE CONSIDERED
----------	-----------------

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

CLG:kmw 264537-1